ReviewJournal of thrombosis and thrombolysis2007
Pathogenesis, clinical and laboratory aspects of thrombosis in cancer.
Review in Journal of thrombosis and thrombolysis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 65 citations in OpenAlex.
- SULF1 and EPB41L3: Potential Biomarkers of Acute Myocardial Infarction and the Vascular Inflammatory Milieu.Journal of inflammation research · 2026Article
- How we manage a high D-dimer.Haematologica · 2024Review
- Haemophilia and Cancer: A Literature Review.Journal of clinical medicine · 2024Review
- Fibrinolysis shutdown and elevated D-dimer levels have high prognostic capacity for postoperative thromboembolic complications in patients with bone tumors.Journal of thrombosis and thrombolysis · 2023Observational
- Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.European journal of clinical pharmacology · 2022Review
- The Hypercoagulable Profile of Patients with Bone Tumors: A Pilot Observational Study Using Rotational Thromboelastometry.Cancers · 2022Article
- Alcohol functionality in the fatty acid backbone of sphingomyelin guides the inhibition of blood coagulation.RSC advances · 2021Article
- Clinical and Prognostic Significance of Lupus Anticoagulant Measurement in Patients With Lung Cancer.Technology in cancer research & treatment · 2017Article
- Safety and efficacy of primary thromboprophylaxis in cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Review
- Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer.BioMed research international · 2017Article
- Comorbidities of cardiovascular disease and cancer in hemophilia patients.Thrombosis journal · 2016Review
- Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma.BMC cancer · 2014Article
- Confusing combination of thrombocytopenia and thrombosis after heparin therapy in a patient with cardiac leiomyosarcoma; a nephrologist viewpoint.Journal of nephropharmacology · 2014Article
- Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond.Journal of molecular medicine (Berlin, Germany) · 2013Review
- Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition.Journal of gynecologic oncology · 2013Article
- Haemophilia and cancer: a personal perspective.Blood transfusion = Trasfusione del sangue · 2013Review
- Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles.Journal of neuro-oncology · 2011Article
- Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality.American journal of hematology · 2009Article
- Cancer and thrombosis: an increasingly important association.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2008Review
- alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis.Molecular and cellular biochemistry · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between increased clotting and malignancy is well recognized, though the bidirectional development of this association is often overlooked. In the challenging cancer biology, transforming genes often act in concert with numerous epigenetic factors, including hypoxia, inflammation, contact between blood and cancer cells, and emission of procoagulant vesicles from tumors, to determine a net imbalance of the hemostatic potential which is detectable by a variety of laboratory tests. Procoagulant factors, in particular, are intimately involved in all aspects of hemostatic, cell proliferation and cellular signalling systems. However, the biggest as yet unresolved question is why cancer patients develop thrombosis? Since the thrombus itself does not apparently contributes directly to the tumor biology, enhanced hemostasis activation in cancer patients may be interpreted according to the most recent biological evidences. Coagulation and cancer biology interact bidirectionally in a "vicious cycle", in which greater tumor burden supplies greater procoagulants (tissue factor, cancer procoagulant) and thrombin, which would in turn act as strong promoters of cancer growth and spread. In this perspective, thrombosis may be interpreted as a epiphenomenon of an intricate an effective biological feedback to maintain or promote cancer progression. In this review article, we briefly analyze the pathogenesis, laboratory, clinical and therapeutic features of cancer and thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.